{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Teva Pharmaceutical Industries Ltd", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Mylan Inc", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "Perrigo Company", "name": "organizations", "rank": "4", "is_major": "Y"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/04/22/business/dealbook/teva-offers-to-acquire-mylan-for-40-billion.html", "document_type": "article", "byline": {"person": [{"lastname": "GELLES", "firstname": "David", "role": "reported", "organization": "", "rank": 1}], "original": "By DAVID GELLES"}, "type_of_material": "News", "multimedia": [{"url": "images/2015/04/22/business/db-drug-web1/db-drug-web1-thumbWide.jpg", "legacy": {"wide": "images/2015/04/22/business/db-drug-web1/db-drug-web1-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2015/04/22/business/db-drug-web1/db-drug-web1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/04/22/business/db-drug-web1/db-drug-web1-articleLarge.jpg", "xlargeheight": "399", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 399}, {"url": "images/2015/04/22/business/db-drug-web1/db-drug-web1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/04/22/business/db-drug-web1/db-drug-web1-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1045", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "The unsolicited offer of $82 a share would scuttle Mylan&#8217;s proposed acquisition of Perrigo in a shake-up of the generic drug industry.", "pub_date": "2015-04-22T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Teva Bids $40 Billion to Acquire a Rival", "main": "Teva, Maker of Generic Drugs, Bids $40 Billion to Acquire Its Rival Mylan"}, "print_page": "1", "snippet": "The unsolicited offer of $82 a share would scuttle Mylan&#8217;s proposed acquisition of Perrigo in a shake-up of the generic drug industry.", "_id": "553652ce38f0d821acced005", "slideshow_credits": null, "abstract": "Israeli generic drug manufacturer Teva makes unsolicited $40 billion offer for Dutch rival Mylan, whose $29 billion bid to acquire Irish drug maker Perrigo is rejected hours later; feverish deal-making comes amid frenzied consolidation that is reshaping the global pharmaceutical industry."}